Anti-angiogenesis drugs mainly target VEGF and VEGF receptors (VEGFR) by inhibiting their expression, which blocks the signal transduction pathway or exhausts the VEGF produced by tumor cells (Figure 1). Here, VEGFA is linked to neoplasm.